Imprimis Pharmaceuticals

San Diego-based Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) is a pharmaceutical company dedicated to delivering high quality and innovative medicines to physicians and patients at accessible prices. Imprimis’ business is focused on its proprietary ophthalmology and urology drug formulations. The company’s pioneering ophthalmology formulation portfolio is disrupting the multi-billion dollar eye drop market, addressing patient compliance issues and providing other medical and economic benefits to patients. Imprimis launched its urology business in early 2015, which includes a patented formulation to address patients suffering from interstitial cystitis.
Company Growth (employees)
Type
Public
HQ
San Diego, US
Founded
2012
Size (employees)
56 (est)
Imprimis Pharmaceuticals was founded in 2012 and is headquartered in San Diego, US

Imprimis Pharmaceuticals Office Locations

Imprimis Pharmaceuticals has an office in San Diego
San Diego, US (HQ)
350 12264 El Camino Real

Imprimis Pharmaceuticals Data and Metrics

Imprimis Pharmaceuticals Financial Metrics

Imprimis Pharmaceuticals's revenue was reported to be $6.1 m in Q1, 2017
USD

Revenue (Q1, 2017)

6.1 m

Gross profit (Q1, 2017)

9.5 m

Gross profit margin (Q1, 2017), %

155%

Net income (Q1, 2017)

(5 m)

EBIT (Q1, 2017)

(4.2 m)

Market capitalization (15-Aug-2017)

47.5 m

Cash (31-Mar-2017)

7.4 m
Imprimis Pharmaceuticals's current market capitalization is $47.5 m.
USDFY, 2014FY, 2015FY, 2016

Revenue

1.7 m9.7 m19.9 m

Revenue growth, %

485%105%

Cost of goods sold

1.1 m5.2 m(9.8 m)

Gross profit

567.4 k4.5 m29.8 m

Gross profit Margin, %

34%46%149%

R&D expense

739 k

General and administrative expense

17.6 m

Operating expense total

10.7 m19.3 m26 m

EBIT

(10.1 m)(14.8 m)(15.9 m)

EBIT margin, %

(611%)(153%)(80%)

Interest expense

3.8 k1.1 m(2.8 m)

Interest income

32.4 k1.1 m

Income tax expense

111 k

Net Income

(10.1 m)(15.9 m)(19.1 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

667.7 k441 k1.6 m2 m2.7 m4.4 m4.9 m4.9 m6.1 m

Cost of goods sold

(239 k)(1 m)(1.1 m)(1.2 m)(2.2 m)(2.2 m)(2.3 m)(3.4 m)

Gross profit

680 k2.6 m3 m3.9 m6.6 m7.1 m7.2 m9.5 m

Gross profit Margin, %

154%164%153%145%151%144%148%155%

R&D expense

35.6 k70.1 k181 k25 k93 k46 k76 k16 k160 k

General and administrative expense

2.3 m2 m2.5 m2.7 m3.1 m3.9 m4.4 m5 m4.4 m

Operating expense total

2.3 m2 m2.7 m2.8 m3.2 m4 m4.5 m5 m4.5 m

EBIT

(2.6 m)(2.5 m)(3.1 m)(3.5 m)(3.5 m)(3.8 m)(4 m)(4.6 m)(4.2 m)

EBIT margin, %

(390%)(557%)(199%)(177%)(132%)(86%)(82%)(95%)(69%)

Interest expense

(1.6 k)(993)(7 k)(249 k)(423 k)(629 k)(631 k)(732 k)(788 k)

Interest income

8.7 k7.5 k(7 k)(249 k)(423 k)

Pre tax profit

(5 m)

Net Income

(2.6 m)(2.5 m)(3.1 m)(3.7 m)(4 m)(4.5 m)(4.6 m)(3.9 m)(5 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

15.6 m8.2 m2.7 m8.9 m

Accounts Receivable

81.3 k840 k2.9 m

Inventories

105.1 k372.7 k1.4 m1.8 m

Current Assets

15.7 m9.1 m5.9 m14.8 m

PP&E

7.3 m

Goodwill

331.6 k2.5 m2.2 m

Total Assets

15.8 m10.2 m14.1 m27.2 m

Accounts Payable

311.9 k786.7 k3.4 m3.5 m

Current Liabilities

650.6 k1.6 m5.4 m9.9 m

Total Liabilities

20.8 m

Additional Paid-in Capital

46.8 m50 m56.4 m83.3 m

Retained Earnings

(41.9 m)(57.8 m)(76.9 m)

Total Equity

15.1 m8.2 m(1.4 m)6.4 m

Financial Leverage

1 x1.3 x-10.2 x4.2 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

12.1 m10.4 m2.9 m10.1 m6.6 m11.8 m5.4 m2.4 m7.4 m

Accounts Receivable

81.1 k68.3 k436 k579 k701 k943 k1.9 m2.2 m3 m

Inventories

172.8 k351.2 k711 k793 k1.3 m1.2 m1.4 m1.9 m2 m

Current Assets

12.8 m11.3 m4.6 m12 m9.4 m14.9 m9.4 m9 m13.6 m

PP&E

7.3 m7.1 m

Goodwill

331.6 k331.6 k1.1 m1.2 m1.4 m2.5 m2.5 m2.2 m2.2 m

Total Assets

13.9 m12.4 m9.4 m16.9 m15 m25.3 m22 m21.5 m25.9 m

Accounts Payable

750.1 k804.2 k1.1 m1.2 m1.9 m4.3 m4 m3.8 m3.9 m

Current Liabilities

1.3 m1.6 m2.2 m2.7 m3.7 m5.7 m5.3 m5.8 m11.8 m

Additional Paid-in Capital

48.7 m49.4 m51.2 m53.9 m54.9 m71 m72.5 m73.6 m87.2 m

Retained Earnings

(36.7 m)(39.1 m)(45 m)(48.7 m)(52.6 m)(62.3 m)(66.9 m)(70.7 m)(81.9 m)

Total Equity

12 m10.3 m6.2 m5.2 m2.2 m8.8 m5.6 m2.8 m5.3 m

Financial Leverage

1.2 x1.2 x1.5 x3.2 x6.7 x2.9 x3.9 x7.6 x4.9 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(7.6 m)(10.1 m)(15.9 m)(19.1 m)

Depreciation and Amortization

5.7 k

Accounts Receivable

(22.9 k)(360 k)(2.1 m)

Inventories

(17 k)(159.5 k)(314 k)(429 k)

Accounts Payable

(239.8 k)345.4 k1 m1.5 m

Cash From Operating Activities

(4.4 m)(7.1 m)(11.1 m)(11.2 m)

Purchases of PP&E

(6.9 m)

Cash From Investing Activities

(70 k)(910.5 k)(5.1 m)(7.3 m)

Cash From Financing Activities

10.1 m598.1 k10.7 m24.7 m

Interest Paid

3.8 k637 k1.4 m

Income Taxes Paid

1.6 k8001 k9 k
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(2.6 m)(2.5 m)(3.1 m)(3.7 m)(4 m)(4.5 m)(4.6 m)(3.9 m)(5 m)

Accounts Receivable

81.1 k68.3 k436 k579 k701 k943 k1.9 m2.2 m3 m

Inventories

172.8 k351.2 k711 k793 k1.3 m1.2 m1.4 m1.9 m2 m

Accounts Payable

750.1 k804.2 k1.1 m1.2 m1.9 m4.3 m4 m3.8 m3.9 m
USDY, 2017

Revenue/Employee

108.9 k

Financial Leverage

4.9 x

Imprimis Pharmaceuticals Market Value History

Traffic Overview of Imprimis Pharmaceuticals

Imprimis Pharmaceuticals Online and Social Media Presence

Imprimis Pharmaceuticals News and Updates

If high-school kids in Australia can replicate a $750 drug for $2, why is it still so expensive to buy?

Martin Shkreli has been the butt of many jokes. The latest one comes from a group of high-school students in Australia. Shkreli is the former…

High school heroes recreate the pill Martin Shkreli priced at $750 for a measly $20

Martin Shkreli swiftly earned transcontinental enmity when back in 2015 the ‘pharma bro’ jacked up the prices of life-saving HIV medication Daraprim from a modest $13.50 to an astronomical $750 overnight. But now it seems an ambitious group of Australian high school students from Sydney has found a …

Mylan will launch a cheaper, generic version of the EpiPen

Mylan will start selling a cheaper version of its EpiPen after absorbing waves of criticism over a list price for the emergency allergy treatment that has grown to $608 for a two-pack, making it unaffordable for many patients without insurance or with high-deductible coverage. The drug maker sai…

Mylan announces cheaper generic EpiPens amid price-gouging accusations

Off-brand injectable allergy medication will cost $300 for a two-pack Opinion: who to blame for EpiPen hike? Drug monopolies – not evil CEOs Mylan will start selling a cheaper version of its EpiPen as criticism mounts over a list price for the emergency allergy treatment that has grown to $608 for…

Mylan launching generic version of EpiPen

NEW YORK (AP) — Mylan says it will make available a generic version of its EpiPen, as criticism mounts over the price of its injectable medicine.The company said Monday that its U.S. subsidiary will put out a generic version of the EpiPen that will have a list price of $300 …

Imprimis Pharmaceuticals Company Life and Culture

You may also be interested in